🟢 Amgen is trading 4.4% up in pre-market on FDA easing and positive Phase 3 results

Amgen is trading 4.4% up in pre-market at $410.35 after positive IMDELLTRA developments.

• The FDA shortened monitoring for the first two doses to six to eight hours from 22 to 24 hours.
• Phase 3 DeLLphi-305 results showed statistically significant improvements in overall and progression-free survival.
• The broader market is modestly firmer, but oncology updates appear to be the clearer catalyst; no pre-market volume data was provided.